接地作为阿尔茨海默病的补充干预:机制,证据和潜在的治疗应用
Sudhir Kshirsagar1, Hemalata Deshmukh2, Arubala P Reddy3
1Department of Internal Medicine, Texas Tech University Health Sciences Center, Lubbock, TX, USA.
Journal of Alzheimer's disease : JAD
|April 22, 2025
概括
接地或接地可以通过减少炎症和氧化应激来帮助对抗阿尔茨海默病 (AD). 这种自然疗法提供了一种安全,具有成本效益的补充方法,以改善患者的生活质量.
科学领域:
- 神经科学是一个神经科学.
- 综合医学是一个整体的医学.
- 老年学是一门学科.
背景情况:
- 阿尔茨海默病 (AD) 是一种进展性神经退行性疾病,其特征是认知能力下降,神经炎症和氧化应激.
- 目前对阿尔茨海默病的治疗方法有限,需要新的治疗策略.
- 接地 (接地) 涉及与地球表面的直接接触,通过吸收自由电子,可能为健康带来好处.
研究的目的:
- 审查通过接地可能影响阿尔茨海默病病理学的生物机制.
- 探索接地与AD相关的抗氧化,抗炎和改善睡眠的潜在作用.
- 评估接地作为AD补充治疗的安全性,可行性和成本效益.
主要方法:
- 关于接地对氧化应激,炎症和皮质醇水平的影响的临床前和临床研究的综述.
- 检查接地对睡眠质量和压力管理的影响.
- 分析接地通过抗氧化和抗炎途径保护神经元健康的潜力.
主要成果:
- 接地表现出潜在的抗氧化和抗炎性质,可以减轻关键的AD病理机制.
- 这种做法可以改善睡眠质量,减少压力,这些因素可以加剧AD的进展.
- 初步证据表明,接地是安全的,可行的,并且具有成本效益,将其定位为实际的补充干预.
结论:
- 接地显示承诺作为阿尔茨海默病的非药物干预方法,通过解决生理和心理方面的问题.
- 进一步的强有力的临床试验至关重要,以验证接地疗法的有效性,特别是在AD人群中.
- 将接地整合到标准护理中可以提高治疗结果,并改善阿兹海默症患者的生活质量.
相关概念视频
Alzheimer's Disease: Treatment
128
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
128
Alzheimer's Disease: Overview
317
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
317


